Table 4.
Acute effectiveness endpoints
| Received VS-guided ablation (N = 1002) |
Paroxysmal AF (n = 801) |
Persistent AF (n = 201) |
P-valuea | |
|---|---|---|---|---|
| Primary acute effectiveness endpoint | ||||
| Patients with PVI at the end of the procedure | 99.7 (99.1–99.9) |
99.9 (99.3–100.0) |
99.0 (96.5–99.9) |
0.104 |
| Secondary acute effectiveness endpoints | ||||
| Patients with PVI by first encirclement | 75.7 (72.9–78.4) |
75.7 (72.6–78.7) |
75.8 (69.2–81.6) |
1.000 |
| Patients with PVI by first encirclement that remained isolated until the end of the procedure | 71.2 (67.8–74.4) |
72.5 (68.7–76.0) |
66.0 (57.8–73.5) |
0.131 |
Completed population (N = 1002).
Data are (%) (95% CI).
AF, atrial fibrillation; PVI, pulmonary vein isolation.
a
Difference between paroxysmal and persistent AF groups by Fisher’s exact test.